Skip to main content

Table 1 Currently approved immunotherapy combinations in cancer

From: Combination strategies to maximize the benefits of cancer immunotherapy

Combinations Indications Approval dates References
Pembrolizumab + pemetrexed /platinum First-line non-squamous NSCLC May 10, 2017 [50, 296]
August 21, 2018
Chemoradiation followed by durvalumab Stage III NSCLC February 16, 2018 [86]
Chemotherapy and pembrolizumab First-line NSCLC October 30, 2018 [52]
Atezolizumab + bevacizumab, paclitaxel and carboplatin First-line NSCLC December 6, 2018 [297]
Atezolizumab + nab-paclitaxel/carboplatin First-line Non-squamous NSCLC December 3, 2019 [51]
Nivolumab + ipilimumab First-line treatment of metastatic or recurrent NSCLC (PD-L1 >  = 1%) May 15, 2020 [298]
Nivolumab + ipilimumab + 2 cycles of Pt chemo First-line treatment of metastatic or recurrent NSCLC May 26, 2020 [299]
Atezolizumab + etoposide/carboplatin ES-SCLC March 18, 2019 [53]
Durvalumab + chemo Extensive SCLC March 30, 2020 [54]
Nivolumab + ipilimumab First-line advanced RCC April 16, 2018 [300]
Axitinib + pembrolizumab First-line advanced RCC April 22, 2019 [301]
Avelumab plus axitinib First-line advanced RCC May 14, 2019 [302]
Nivolumab + cabozantinib First-line advanced RCC January 22, 2021 [303]
Chemotherapy, trastuzumab and pembrolizumab Advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma May 5, 2021 [304]
Chemotherapy + pembrolizumab Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma March 23, 2021 [305]
Atezolizumab + nabpaclitaxel Metastatic triple negative breast March 8, 2019 [55]
Pembrolizumab + chemotherapy Recurrent or metastatic triple negative breast November 13, 2020 [56]
Pembrolizumab + chemotherapy HNSCC June 11, 2019 [57]
Pembrolizumab + lenvatinib Endometrial carcinoma September 17, 2019 [306]
Nivolumab + ipilimumab Previously untreated unresectable malignant pleural mesothelioma October 2, 2020 [307]
Nivolumab + ipilimumab Hepatocellular carcinoma after Sorafenib March 11, 2020 [308]
Atezolizumab + bevacizumab HCC 1st-line May 29, 2020 [309]
Nivolumab + ipilimumab Salvage MSI-H/dMMR metastatic CRC July 11, 2018 [310]
Nivolumab + ipilimumab BRAFWT Metastatic melanoma October 1, 2015 [311]
Nivolumab + ipilimumab Metastatic melanoma across BRAF status January 23, 2016 [312]
Atezolizumab + cobimetinib and vemurafenib BRAF V600 + advanced melanoma July 30, 2020 [313]
Chemotherapy followed by avelumab Locally advanced or metastatic urothelial carcinoma June 30, 2020 [58]